Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | AURKA | O14965 | 9/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | FLT3 | P36888 | 5/20 | 0.49 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | PLK4 | O00444 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705046 | 0.92 | EGFR (0.54) | EGFRAURKAKDRFLT3FLT1 | |
| SCHEMBL16065616 | 0.91 | EGFR (0.53) | EGFRAURKAKDRFLT3FLT1 | |
| SCHEMBL16065675 | 0.90 | EGFR (0.50) | EGFRAURKAKDRFLT3FLT1 | |
| SCHEMBL16065657 | 0.90 | EGFR (0.61) | EGFRAURKATBK1PIK3C3SRC | |
| SCHEMBL16065643 | 0.89 | EGFR (0.49) | EGFRAURKAFLT3NTRK1TBK1 | |
| SCHEMBL15704837 | 0.88 | EGFR (0.48) | EGFRAURKANTRK1TBK1PIK3C3 | |
| SCHEMBL16065611 | 0.86 | EGFR (0.51) | EGFRAURKATBK1PIK3C3SRC | |
| SCHEMBL15704873 | 0.86 | EGFR (0.51) | EGFRAURKATBK1PIK3C3SRC | |
| SCHEMBL17175935 | 0.86 | EGFR (0.53) | EGFRAURKAKDRFLT3FLT1 | |
| SCHEMBL15704942 | 0.85 | EGFR (0.46) | EGFRAURKATBK1PIK3C3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9458137-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2014145403-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | EGFR 668/4885AURKA 796/4885KDR 1410/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | EGFR 658/4885AURKA 1063/4885KDR 1032/4885 |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | GRK5, GRK3, CDK5 | EGFR 668/4885AURKA 796/4885KDR 1410/4885 |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | EGFR 658/4885AURKA 1063/4885KDR 1032/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | EGFR 668/4885AURKA 796/4885KDR 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.